Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tazemetostat in COVID-19 ARDS and SCRS
NCT05018975Phase 2Withdrawn
- Sponsor
- Loma Linda University
- Start
- Jan 2022
- Primary completion
- Sep 2023
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of tazemetostat in COVID-19-associated acute respiratory distress syndrome (CARDS), cytokine release syndrome (CRS), sponsored by Loma Linda University. Planned start Jan 2022; status: withdrawn.
02
Drugs
tazemetostat
03
Conditions
COVID-19-associated acute respiratory distress syndrome (CARDS)cytokine release syndrome (CRS)
Beyond the preview
Go deeper on NCT05018975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05018975.